Switch theme
Sign up to access all valuation multiples
Dimed SA Distribuidora de Medicamentos is engaged in the sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics. Its segments are divided into Retail, Wholesale and Corporate. The Retail segment has 556 stores that sell more than 15,000 items among drugs and personal care and beauty products. The Wholesale segment is the distributor of drugs in Brazil. The Corporate segment includes Wholesale and Retail, as well as the subsidiary Lifar. In addition to adding divisions of cosmetics, drugs and food, Lifar is responsible for the production of brands in Brazil, as well as products of its own brand Panvel.
1967
n/a
LTM Revenue $987M
LTM EBITDA $73.5M
$459M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Dimed Distribuidora has a last 12-month revenue (LTM) of $987M and a last 12-month EBITDA of $73.5M.
In the most recent fiscal year, Dimed Distribuidora achieved revenue of $909M and an EBITDA of $78.7M.
Dimed Distribuidora expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Dimed Distribuidora valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $987M | XXX | $909M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $289M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 32% | XXX | XXX | XXX |
| EBITDA | $73.5M | XXX | $78.7M | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 9% | XXX | XXX | XXX |
| EBIT | $46.9M | XXX | $36.6M | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $24.6M | XXX | $19.4M | XXX | XXX | XXX |
| Net Margin | 2% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $87.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 18, 2025, Dimed Distribuidora's stock price is BRL 10 (or $2).
Dimed Distribuidora has current market cap of BRL 1.5B (or $272M), and EV of BRL 2.5B (or $459M).
See Dimed Distribuidora trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $459M | $272M | XXX | XXX | XXX | XXX | $0.18 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 18, 2025, Dimed Distribuidora has market cap of $272M and EV of $459M.
Dimed Distribuidora's trades at 0.5x EV/Revenue multiple, and 5.8x EV/EBITDA.
Equity research analysts estimate Dimed Distribuidora's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dimed Distribuidora has a P/E ratio of 11.0x.
See valuation multiples for Dimed Distribuidora and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $272M | XXX | $272M | XXX | XXX | XXX |
| EV (current) | $459M | XXX | $459M | XXX | XXX | XXX |
| EV/Revenue | 0.5x | XXX | 0.5x | XXX | XXX | XXX |
| EV/EBITDA | 6.2x | XXX | 5.8x | XXX | XXX | XXX |
| EV/EBIT | 9.8x | XXX | 12.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 11.0x | XXX | 14.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 37.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDimed Distribuidora's last 12 month revenue growth is 11%
Dimed Distribuidora's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Dimed Distribuidora's rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Dimed Distribuidora's rule of X is 36% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Dimed Distribuidora and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 2% | XXX | XXX | XXX |
| Rule of 40 | 20% | XXX | 20% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 36% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Profarma Distribuidora | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dimed Distribuidora acquired XXX companies to date.
Last acquisition by Dimed Distribuidora was XXXXXXXX, XXXXX XXXXX XXXXXX . Dimed Distribuidora acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Dimed Distribuidora founded? | Dimed Distribuidora was founded in 1967. |
| Where is Dimed Distribuidora headquartered? | Dimed Distribuidora is headquartered in Brazil. |
| Is Dimed Distribuidora publicy listed? | Yes, Dimed Distribuidora is a public company listed on BVMF. |
| What is the stock symbol of Dimed Distribuidora? | Dimed Distribuidora trades under PNVL3 ticker. |
| When did Dimed Distribuidora go public? | Dimed Distribuidora went public in 1995. |
| Who are competitors of Dimed Distribuidora? | Similar companies to Dimed Distribuidora include e.g. MedPlus India, SC Ropharma, Profarma Distribuidora, Pague Menos. |
| What is the current market cap of Dimed Distribuidora? | Dimed Distribuidora's current market cap is $272M |
| What is the current revenue of Dimed Distribuidora? | Dimed Distribuidora's last 12 months revenue is $987M. |
| What is the current revenue growth of Dimed Distribuidora? | Dimed Distribuidora revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Dimed Distribuidora? | Current revenue multiple of Dimed Distribuidora is 0.5x. |
| Is Dimed Distribuidora profitable? | Yes, Dimed Distribuidora is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Dimed Distribuidora? | Dimed Distribuidora's last 12 months EBITDA is $73.5M. |
| What is Dimed Distribuidora's EBITDA margin? | Dimed Distribuidora's last 12 months EBITDA margin is 7%. |
| What is the current EV/EBITDA multiple of Dimed Distribuidora? | Current EBITDA multiple of Dimed Distribuidora is 6.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
